

## HEPATOPANCREATOBILIARY CANCER PROGRAM OVERVIEW

We provide the people we care for with:

- the latest minimally invasive, image-guided techniques for diagnosis and treatment
- the benefit of seeing three or four specialists on one day, in one location
- an individualized treatment plan
- a comprehensive risk assessment and long-term surveillance program
- access to innovative clinical trials of chemotherapies, surgical techniques, and advanced technologies that are not available at other hospitals
- genomic sequencing to look for actionable mutations
- non opioid analgesic options for postoperative pain relief

## LOCATIONS

Many of our specialists are centrally located at our **Manhattan location**. We also have regional outpatient locations at:

- MSK Basking Ridge, New Jersey
- MSK Commack, New York
- MSK Rockville Centre, New York

### REFER A PATIENT

Contact our [Physician Access Service](#) directly at

# 800-525-2225

MSK has insurance contracts with most major health plans in the New York tristate area.

### Our Team Leaders

**William Jarnagin, MD, FACS**  
Chief, Hepatopancreatobiliary Service;  
Leslie Blumgart Chair in Surgery

**Mark Schattner, MD, FASGE, AGAF**  
Chief, Gastroenterology, Hepatology and  
Nutrition Service

**Michael D'Angelica, MD, FACS**  
Enid A. Haupt Chair in Surgery;  
Director, Hepatopancreatobiliary Fellowship  
Program; Director, Surgical Oncology  
Fellowship Program

**Jeffery Drebin, MD, PhD**  
Chair, Department of Surgery

**Christopher Crane, MD**  
Vice Chair, Department of Radiation Oncology

**T. Peter Kingham, MD, FACS**  
Director, Global Cancer Disparity Initiatives

**Eileen O'Reilly, MD**  
Associate Director for Clinical Research,  
David M. Rubenstein Center for Pancreatic  
Cancer Research

**Ghassan Abou-Alfa, MD**  
Medical Oncologist

**Karen Brown, MD, FSIR**  
Interventional Radiologist

Sign up for **OncoNotes**, MSK's clinical updates newsletter.

Go to [MSKCC.org](#), click on the **For Health Professionals** section, and choose "Sign up for Our E-newsletter."



Memorial Sloan Kettering  
Cancer Center



## Hepatopancreatobiliary Cancer Program



Memorial Sloan Kettering  
Cancer Center



### Advanced Technologies

- We use the latest laparoscopic and image-guided, robotic surgical techniques, resulting in **greater precision, fewer complications, decreased postoperative pain, shorter hospital stays, and faster recovery** times compared with open surgery.
- We utilize **virtual surgical planning and prognostic imaging markers** to make diagnoses and determine treatment responses.
- We developed **advanced radiotherapy techniques** with ablative doses for longer-term local tumor control and survival rates in people with inoperable hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
- Our **24-7 pathology lab** processes digitized images of tissue samples very quickly, including during surgery, to help patients avoid unnecessary procedures.

## WHY CHOOSE MSK FOR HEPATOPANCREATOBILIARY CANCER CARE?

### Expertise

- Our **hepatopancreatobiliary cancer experts** treat liver, gallbladder, bile duct, pancreatic, and gastroneuroendocrine cancers.
- We routinely use **MSK-IMPACT™, a genome-sequencing test** developed at MSK that allows us to quickly determine if tumors have mutations that are actionable with available targeted therapies or if patients may benefit from clinical trials.
- We pioneered the **hepatic parenchymal preservation surgical approach**, which has significantly decreased morbidity and mortality rates after partial hepatectomy.

### Leadership

- We **diagnose and treat more people with liver, pancreatic, and bile duct cancer** than any other cancer center in the United States.
- Our surgeons are **global leaders in minimally invasive surgical techniques**.
- Over the past 25 years, we have pioneered liver-directed hepatic arterial infusion (HAI) chemotherapy for people with colorectal liver metastases. Our experts recently published results showing that **adding HAI extends survival significantly, by almost two years**, compared with standard chemotherapy alone.
- We have **more than 25 hepatobiliary clinical trials underway** for a broad range of targeted therapies, emerging immunotherapies, and novel surgical approaches.

### By the Numbers

**1,000**

Hepatopancreatobiliary patient visits per year

**4** locations

**8**

gastroenterologists



**200+**  
Disease Management Team members

**17**

medical oncologists